

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 09/20/2006

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/643,659	08/19/2003	Matthew O'Donnell	UOM 0276 PUSP	5262
22045	7590 09/20/2006		EXAMINER	
BROOKS KUSHMAN P.C. • 1000 TOWN CENTER			KISH, JAMES M	
TWENTY-SECOND FLOOR			ART UNIT	PAPER NUMBER
SOUTHFIELI	D, MI 48075	·	3737	,

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/643,659	O'DONNELL ET AL.
Office Action Summary	Examiner	Art Unit
	James Kish	3737
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING E - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tin I will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 2a) ☐ This action is FINAL . 2b) ☑ This action is application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matters, pro	
Disposition of Claims		
4) Claim(s) 1-52 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) 1,2,4-9,13-19,21-26,28-33,37-43 and 7) Claim(s) 3,10-12,20,27,34-36 and 44 is/are o 8) Claim(s) are subject to restriction and/ Application Papers 9) The specification is objected to by the Examin 10) The drawing(s) filed on 19 August 2003 is/are Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examin 10.	awn from consideration. d 45-52 is/are rejected. bjected to. for election requirement. er. a) accepted or b) objected by drawing(s) be held in abeyance. Section is required if the drawing(s) is objected.	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	nts have been received. Its have been received in Applicat ority documents have been received au (PCT Rule 17.2(a)).	ion No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 9/2/03, 2/2/04.	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate

Application/Control Number: 10/643,659

Art Unit: 3737

DETAILED ACTION

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-2, 4-8, 17-18, 21-26, 28-32, 41-42 and 45-52 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sliwa, Jr. et al. (US Patent No. 5,749,364) in view of Mackinnon et al. (US Patent No. 6,546,272). Sliwa discloses a method of mapping fluid pressure information within a living body utilizing changes in acoustic behavior of microbubbles. It is also possible to use this information to assess the health of tissue (see Abstract). High frequency sound waves are applied to the region containing the microbubbles and an acoustic spectrum returned from the region (to a detector). A fluid pressure parameter is determined in response to at least one characteristic of the acoustic spectrum (column 3, lines 29-40). The pressure-related information is displayed in at least 2 dimensions (column 4, lines 56-63). Also, see column 3, line 65 through column 4, line 11 for discussion on evaluation of the health of bodily tissue. Sliwa uses an ultrasound transmitter to create the ultrasound wave. However, Mackinnon teaches an apparatus for in vivo imaging of internal organs. In one technique, a laser (with a focused beam; column 5, lines 33-35) is directed into tissue to create a microbubble of gas or plasma. When the bubble collapses, an ultrasound pulse is generated which is measured by a piezoelectric crystal detector

(column 5, line 65 through column 6, line 2). Therefore, it was known in the art at the time the invention was made that a laser is capable of creating both microbubbles and ultrasonic waves that can be detected. It would have been obvious to one having ordinary skill in the art at the time the invention was made to use a laser, as taught by Mackinnon, either in combination with or as an alternative to an ultrasound emitter to cause an acoustic wave associated with a microbubble to propagate in a volume of interest and be detected and analyzed to evaluated pressure of the surrounding environment, as disclosed by Sliwa, in order to remove the need of prefabricating

With regard to claims 21-22 and 45-46 see column 1, line 55 through column 2, line 10, as well as column 2, lines 31-35 of Sliwa.

With respect to claims 4 and 28, see column 6, lines 10-26 of Sliwa.

microbubbles using polymers (Sliwa: column 1, lines 37-42).

Claims 19 and 43 rejected under 35 U.S.C. 103(a) as being unpatentable over Sliwa, Jr. et al. in view of Mackinnon et al. as applied to claims 1-2, 4-8, 17-18, 21-26, 28-32, 41-42 and 45-52 above, and further in view of Esenaliev (US Patent No. 6,165,440). Sliwa in combination with Mackinnon teach the use of laser-induced microbubbles to create acoustic waves, which can be detected and analyzed, as descried above. However, neither reference includes ultrafast pulses or additives. Esenaliev teaches interaction of electromagnetic pulses with nanoparticles for enhancement of drug delivery (see Abstract). The pulses can be on the level of short (nanoseconds) or ultrashort (picoseconds) as described at column 6, lines 40-44. It

Art Unit: 3737

would have been obvious to one having ordinary skill in the art at the time the invention was made to use ultrafast laser pulses with the additives described by Esenaliev in the system of Sliwa/Mackinnon because porous particles with gas-filled pores can substantially lower cavitation threshold because they already have initial bubbles, thereby (column 10, lines 22-35).

Claims 9, 13-16, 33, and 37-40 rejected under 35 U.S.C. 103(a) as being unpatentable over Sliwa, Jr. et al. in view of Mackinnon et al. as applied to claims 1-2, 4-8, 17-18, 21-26, 28-32, 41-42 and 45-52 above, and further in view of Baker, Jr. et al. (US Patent No. 6,471,968). Sliwa in combination with Mackinnon teach the use of laser-induced microbubbles to create acoustic waves, which can be detected and analyzed, as descried above. However, neither reference includes nanodevices as part of an additive. Baker teaches a therapeutic and diagnostic array comprising nanodevices used for delivery of therapeutic agents (column 6, lines 49-67). For description of the device, see column 12. For therapeutic agents used with the device, see column 15. It would have been obvious to one having ordinary skill in the art at the time the invention was made to include the nanodevices as taught by Baker into the system of Sliwa/Mackinnon in order to actively determine time and location of the distribution of therapeutic agents and to monitor the response to therapy of a cell or tissue (see Abstract).

Art Unit: 3737

Allowable Subject Matter

Claims 3, 10-12, 20, 27, 34-36 and 44 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James Kish whose telephone number is 571-272-5554. The examiner can normally be reached on 8:30 - 5:00 ~ Mon. - Fri..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 571-272-4956. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

JMK

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700